Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.
about
To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic VirusesOverview of current immunotherapeutic strategies for gliomaGene therapy for brain tumors: basic developments and clinical implementationDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsHMGB1 mediates endogenous TLR2 activation and brain tumor regressionCombining cytotoxic and immune-mediated gene therapy to treat brain tumorsHuman gene therapy and imaging in neurological diseases.Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regressionHuman Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.Advances in preclinical investigation of prostate cancer gene therapy.Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsMarmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathologyRegulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses.Current status of gene therapy for brain tumors.Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain.Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells.Gene therapy and targeted toxins for glioma.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cellsAdenoviral-mediated gene transfer into the canine brain in vivo.Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer modelGene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms.Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear CellsImmune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactionsSpecific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification systemSafety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialHigh-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.Efficacy of nonviral gene transfer in the canine brain.Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.
P2860
Q26767212-C9B9EDFC-5A9F-4FC1-A8C2-E064702031B1Q26776345-F56E8694-E296-43B7-994D-6343754A8B28Q26829086-56316480-654B-49E2-A862-FCB52D1E31DCQ27014829-0181BE5B-9154-4825-9ECB-44426E8EDDCEQ27307459-6CEF1478-6D22-4294-9919-C158BFE7C2E5Q31013320-3A658829-2F41-4872-9843-290069641359Q31023442-0F2647A1-A5A4-4C37-B0DE-AA475CEA90A3Q33330270-6C3B3A44-1745-46C8-A662-4CD1C2FCE3E8Q33551268-A67C24D5-F0E4-4ADC-B525-436DCD99C223Q33605719-E6F85A26-628A-4A3A-B55A-505C7A7EC2D5Q33670136-523F0CEC-5BC0-4A1A-BDCA-9F18EBE8AB2BQ33677054-8FA6ACBB-BECB-44EF-B38D-E3EFAFB250D3Q33828102-25703489-A879-4C26-A2AD-5FF6C6FDDE29Q33828114-4AD9C13A-1957-4F1D-A331-CB15F7198703Q33877450-3404F227-716F-436E-9696-36AA545E47FCQ33950709-A3DC10D2-4B7C-4976-A201-440BD58E5781Q34012284-77C632D3-07B3-4DDF-8A2A-BAE78965CFABQ34022048-C3C9965E-9AFF-4C62-88AF-71159A5E730EQ34069598-B32D0E5B-40FF-4B5D-921C-8CD6595FAA09Q34233124-7AF26DD0-AFE7-47B0-BF15-119B0CD8071EQ34318157-73DC725B-37A6-4B28-AE9D-3779D86D68E1Q34647123-E448453D-9E91-4F3C-8FBC-4F2330D038AAQ35069546-DC5FE68B-0442-4114-BE42-A29A74F04756Q35118919-7324295B-2610-40C8-BF21-E077AEFD25DCQ35118933-44DA6707-09E2-4A8B-9A84-550A1F2E21BDQ35285859-D5F75875-BC6D-4139-AE22-57E6694EDDE1Q35527165-267264EA-F52F-4272-B0E3-ED397F9BA655Q35870480-6D7413BB-4CB5-432F-8290-280571D495F7Q35876228-63A0D883-4B9F-41B4-9F0E-656D5FF96D9CQ36172992-DC3032DE-4FE5-4D58-B6CB-ECB2362B70FFQ36200438-81D4DBDD-8008-4DAB-B792-F3CBAF982243Q36345439-D677AFCE-70DE-4243-A510-5C075C3E0C63Q36367568-9112063A-FD1A-469B-B2D1-7B1009ACF57FQ36408364-32C7D37A-8306-4A85-8F79-E7D27F805A35Q36498773-BFDE9CB8-752D-4AC5-9146-EACB7005C903Q36512533-F3F1D434-9AAD-4341-AACA-857B2323707FQ36534329-E09976BC-D58C-42E5-9205-31F99C3B405DQ36540199-21A4F867-86D4-4598-BC11-6F205DCDC29DQ36658314-8F4760AA-422C-480B-AA08-28DA6A8BA956Q36658322-DCD329EF-567A-4F41-A33B-CA85E94C85F7
P2860
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Combined immunostimulation and ...... vival in a large glioma model.
@ast
Combined immunostimulation and ...... vival in a large glioma model.
@en
Combined immunostimulation and ...... vival in a large glioma model.
@nl
type
label
Combined immunostimulation and ...... vival in a large glioma model.
@ast
Combined immunostimulation and ...... vival in a large glioma model.
@en
Combined immunostimulation and ...... vival in a large glioma model.
@nl
prefLabel
Combined immunostimulation and ...... vival in a large glioma model.
@ast
Combined immunostimulation and ...... vival in a large glioma model.
@en
Combined immunostimulation and ...... vival in a large glioma model.
@nl
P2093
P2860
P50
P1433
P1476
Combined immunostimulation and ...... rvival in a large glioma model
@en
P2093
Antoni Ribas
Chunyan Liu
Gwendalyn D King
Jerzy Kupiec-Weglinski
Mariana Puntel
Marianela Candolfi
Nico van Rooijen
Pedro R Lowenstein
Queng Cheng
P2860
P304
P356
10.1158/0008-5472.CAN-04-3434
P407
P577
2005-08-01T00:00:00Z